Inhibiting TREX1 is a unique approach with great potential to enhance the effect of several current therapies. Many modern cancer drugs depend on the immune system being able to identify the cancer cells, and with our TREX1 inhibitors, we have identified a way to stop the cancer cells' ability to hide from the immune system. We have now reached a strong competitive position in the program's development and look forward to discussions with potential partners.

We have once again been able to identify a target protein that constitutes a very attractive starting point for a new drug program. The ambition is to influence the microenvironment of the tumors so that the growth of cancer cells is inhibited and the body's immune system can more easily fight them. We will in a time- and resource-efficient way drive the project to a point where it can dock into an international pharmaceutical company's portfolio and be taken further to clinic development towards the market and cancer patients who need new treatment option

Immunotherapy is showing tremendous benefits in cancer but unfortunately the majority of cancer patients do not respond to current immunotherapy approaches. There is therefore a great need to increase the tumor’s susceptibility of attack from the immune system, and here inhibitors of the protein Vps34 may play an important role.

We thank Anders Åberg for all the fantastic work that has led to Sprint Bioscience becoming the high-quality company it is today.

We are very happy to have entered into this agreement with LG Chem Life Sciences Company, a perfect partner to further develop this program.

Leveraging Sprint Bioscience’s expertise in fragment-based drug discovery capability and LG Chem Life Sciences’ capability in pharma-ceutical development, we aim to accelerate bringing new treatment options for NASH and metabolic syndrome.

Patent protection gives us an edge over others in the field

We know from our contacts with the pharmaceutical industry that immuno-oncology is an area where demand for new projects is high

We are really happy to have closed a deal with a company with world leading expertise in tumor metabolism biology. It will increase the chances to develop a drug to the benefit for cancer patients.

To combine frontline research with our platform for fast and resource efficient development of drugs, together with the Lundberg Laboratory for Diabetes Research, provides great opportunities for Sprint Bioscience to develop a new cure for T2D

I look forward to working with Sprint Bioscience in this project. Together, we will develop inhibitors that affect a central mechanism for insulin resistance

We are very happy to have entered into this agreement for one of our tumor metabolism projects. We are convinced that Bayer is a perfect partner to further develop this program.

We are looking forward to expanding our portfolio in this area through the agreement with Sprint Bioscience. This early research program has the potential to lead to new treatment options for cancer patients.